ECM
GRNA

ExodusPoint Capital Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

ExodusPoint Capital Management’s Portfolio GRNA Stock Details GRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-42,231
Closed -$407K – 2643
2022
Q1 		$407K Buy
+42,231
New +$378K 0.01% 1643

Other funds holding GRNA

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
CGC
Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's GRNA Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q2 2022, closing a stake of 42,231 shares — an estimated $407K sold.

ExodusPoint Capital Management first reported a position in GRNA in Q1 2022 and held it in 1 quarter. The position peaked at $407K in Q1 2022. 50 funds tracked by Wall St. Rank hold GRNA as of Q2 2022.

  • ExodusPoint Capital Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q2 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 42,231 GreenLight Biosciences Holdings, PBC Common Stock shares in Q2 2022, an estimated $407K.
  • ExodusPoint Capital Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2022 and held it in 1 quarter.
  • ExodusPoint Capital Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $407K in Q1 2022.
  • 50 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.